| Home > Business | ||
|
Services available for use by third parties |
Technologies available for license
St George’s, University of London St George’s is able to offer a range of technologies to commercial partners including: A vaccine treatment for Crohn’s Disease Chronic inflammation of the intestines in many animal species including primates is caused by MAP (mycobacterium avium subspecies paratuberculosis) and it is postulated that the same organism causes Crohn’s disease in man. A patented DNA vaccine has been developed which has shown effectiveness in preclinical studies. This patented diagnostic test provides objective assessment of whether an individual is addicted to opioids or not. The principle advantage over other drug tests is that it differentiates between addiction and casual use. It has been validated clinically and is ready for out-licensing. A diagnostic test for Tuberculosis From the analysis of a broad range of patient serum samples, a set of diagnostic markers for TB has been detected. It is anticipated that the test and analysis may be incorporated into a hand held diagnostic device for use at point of care. The test is ready to be developed into a prototype device or out-licensed. An early detection test for pre-eclampsia The aim is to develop a predictive test for those pregnancies that go on to develop pre-eclampsia. They have carried out a preliminary analysis of a small patient group and potential diagnostic markers have been identified. Better prediction of the condition would allow earlier and more effective clinical intervention and as a spin off, the research might also identify novel therapeutic targets for treatment. Reagent business for drug discovery and development This project seeks to market and further develop unique biologicals for research & development of drugs. The work aims to treat infective disease, neurodisease and cancer. Long term plans include expansion of the business into a drug discovery company. Target for Acute Coronary Syndrome Therapy Researchers at St George’s have their sights set on using a novel therapeutic agent to treat conditions such as angina and acute coronary syndrome. The team, lead by a highly skilled clinician is investigating the use of a panel of biomarkers for risk assessment for significant stratification of patients with angina. They are also investigating the immunological basis of atherosclerosis aetiology. HXP peptide: Product and Method The invention relates to molecules which impair PBX-dependent transcription regulation, particularly peptides which affect the binding of HOX to PBX and their use in a number of applications, including the reduction of aberrant or unwanted cell division. In vitro data suggest that the HXP peptide will improve prognosis of a range of cancers. HXP can block proliferation of malignant cells whilst forcing them to come out of the cell cycle and differentiate, thus making these cells more sensitive to chemotherapeutic agents whilst protecting stem cells. Dr Angela Collins
|
|
